Company Focus

Merck & Co

Latest Merck & Co News

Beyfortus gains boost from real-world data as RSV battle heats up
Biotechnology
A large-scale real-world study in the USA has reinforced the effectiveness of Beyfortus (nirsevimab-alip), the respiratory syncytial virus (RSV) preventive developed by French drugmaker Sanofi and UK-based AstraZeneca.   23 July 2025


Insights

Company Spotlight

Latest News & Features of interest to Merck & Co

Latest Related Ones To Watch News

Related Ones to Watch Companies

Reset all filters
Refine Search